TY - JOUR
T1 - Clinical features of gastrointestinal follicular lymphoma
T2 - Comparison with nodal follicular lymphoma and gastrointestinal MALT lymphoma
AU - Tari, Akira
AU - Asaoku, Hideki
AU - Kunihiro, Masaki
AU - Tanaka, Shinji
AU - Fujihara, Megumu
AU - Yoshino, Tadashi
PY - 2011/1
Y1 - 2011/1
N2 - We retrospectively compared the clinicopathological features of primary intestinal follicular lymphomas (FL-GIs), nodal follicular lymphomas (FL-LNs) and gastrointestinal MALT lymphomas (MALT-GIs), and investigated the distribution and the endoscopic appearances of FL-GI to evaluate the effectiveness of treatment modality. The subjects were 28 FL-GI patients, 135 FL-LN patients and 70 MALT-GI patients. In FL-LNs the clinical stage III-IV was 83%, while in FL-GIs clinical stage I-II was 68%. In MALT-GIs clinical stage I-II was 87%. The overall survival was significantly better in MALT-GI patients than in FL-LN patients. All FL-GI patients were alive at the time of evaluation. Regarding the histological grade (WHO), grade 1 was 81% in FL-GI, whereas in FL-LN grade 2 was 28% and grade 3 was 11%. The Follicular Lymphoma International Prognostic Index was low in 61% of FL-GIs, while in FL-LNs it was equally distributed to low, intermediate and high, suggesting that the prognosis is better in FL-GIs than in FL-LNs. The clinicopathological studies revealed the FL-GI has intermediate characteristics between FL-LN and MALT-GI. We recommend a 'watch-and-wait' policy or chemotherapy with rituximab for the therapy of FL-GIs because the lesions are often located in broader areas from the lower duodenum to the small intestine.
AB - We retrospectively compared the clinicopathological features of primary intestinal follicular lymphomas (FL-GIs), nodal follicular lymphomas (FL-LNs) and gastrointestinal MALT lymphomas (MALT-GIs), and investigated the distribution and the endoscopic appearances of FL-GI to evaluate the effectiveness of treatment modality. The subjects were 28 FL-GI patients, 135 FL-LN patients and 70 MALT-GI patients. In FL-LNs the clinical stage III-IV was 83%, while in FL-GIs clinical stage I-II was 68%. In MALT-GIs clinical stage I-II was 87%. The overall survival was significantly better in MALT-GI patients than in FL-LN patients. All FL-GI patients were alive at the time of evaluation. Regarding the histological grade (WHO), grade 1 was 81% in FL-GI, whereas in FL-LN grade 2 was 28% and grade 3 was 11%. The Follicular Lymphoma International Prognostic Index was low in 61% of FL-GIs, while in FL-LNs it was equally distributed to low, intermediate and high, suggesting that the prognosis is better in FL-GIs than in FL-LNs. The clinicopathological studies revealed the FL-GI has intermediate characteristics between FL-LN and MALT-GI. We recommend a 'watch-and-wait' policy or chemotherapy with rituximab for the therapy of FL-GIs because the lesions are often located in broader areas from the lower duodenum to the small intestine.
KW - Follicular lymphoma
KW - Gastrointestinal MALT lymphoma
KW - Gastrointestinal follicular lymphoma
KW - Mucosa-associated lymphoid tissue
KW - Nodal follicular lymphoma
UR - http://www.scopus.com/inward/record.url?scp=79251585243&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79251585243&partnerID=8YFLogxK
U2 - 10.1159/000321814
DO - 10.1159/000321814
M3 - Article
C2 - 21266815
AN - SCOPUS:79251585243
SN - 0012-2823
VL - 83
SP - 191
EP - 197
JO - Digestion
JF - Digestion
IS - 3
ER -